- Top page >
- Greetings
Head: Osamu Takikawa, PhD
Lab. Drug Screening,
Dep. Drug Discovery,
Center for Advanced Medicine for Dementia (CAMD)
Greetings
Here Japan is one of the most longevous countries in the world. So
it is worrying about the healthcare spending for the elderly becoming
to most advanced within these 20 years.
We are studying about
A. Screening system of PET chemical for detecting tau aggregates
for difinite diagnosis,
B. Searching a factor for inhibiting the protein aggregation,
and
C. Conducting a basic research for preventative medicine for
dementia.
(PET: positron emission tomography)
Also head of the laboratory of Radiation Safety
Diagnosis and the prevention for dementia
We are searching a new category of high affinity chemical with
protein aggregation in the brain using a high throughput robotic
screening system. It is becoming a lead compound if we could get such
chemicals possessing the high binding affinity to the aggregation. We
will synthesize the derivatives of the lead, then analyse the safety in
the animal test, following test for the diagnostic or therapeutic
product.
# There are no PET chemicals which can difine the types of dementia, we
are detecting the chemicals with studying the basic science of demetia.
We are about to establish a new method for searching the diagnostic
chemicals, then exploring the preventative drugs for the dementia in
the near future.
Major publication (2012~)
| [Literature] |
|---|
| Tanizaki Y, Kobayashi A, Toujima S, Shiro M, Mizoguchi M, Mabuchi Y, Yagi S,Minami S, *Takikawa O, Ino K. Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer via inducing immunosuppressive environment. Cancer Sci. 105:966-973, 2014. |
| Lu M, Williamson NR, Boschetti C, Ellis T, *Yoshimi T, Tunnacliffe A. Expression-level dependent perturbation of cell proteostasis and nuclear morphology by aggregation-prone polyglutamine proteins. J Biol Chem, in press. |
| Higashitani K, Kanto T, Kuroda S, Yoshio S, Matsubara T, Kakita N, Oze T, Miyazaki M, Sakakibara M, Hiramatsu N, Mita E, Imai Y, Kasahara A, Okuno A, *Takikawa O, Hayashi N, Takehara T. Association of enhanced activityof indoleamine 2,3-dioxygenase in dendriticcells with the induction of regulatory T cells in chronic hepatitis C infection. J Gastroenterol. 2013 May;48(5):660-70. |
| Wright O, Zhang L, Liu Y, *Yoshimi T, Zheng Y, Tunnacliffe A. Critique of the use of fluorescence-based reporters in Escherichia coli as a screening tool for the identification of peptide inhibitors of Aβ42 aggregation. J Pept Sci. 19:74-83, 2013. |
| *Okada K, Angkawidjaja C, Koga Y, Takano K, Kanaya S. Characteristic features of kynurenine aminotransferase allosterically regulated by (alpha)-ketoglutarate in cooperation with kynurenine. PLoS One. 7:e40307, 2012. |
| Sato N, Saga Y, Mizukami H, Wang D, Takahashi S, Nonaka H, Fujiwara H, Takei Y, Machida S, *Takikawa O, Ozawa K, Suzuki M. Downregulation of indoleamine-2,3-dioxygenase in cervical cancer cellssuppresses tumor growth by promoting natural killer cell accumulation. Oncol Rep. 28:1574-1578, 2012. |
| Tanaka M, Li X, Hikawa H, Suzuki T, Tsutsumi K, Sato M, *Takikawa O,Suzuki H, Yokoyama Y. Synthesis and biological evaluation of novel tryptoline derivatives asindoleamine 2,3-dioxygenase (IDO) inhibitors. Bioorg Med Chem. 21:1159-1165, 2013. |
| Fukuhara K, Ohno A, Ota Y, Senoo Y, Maekawa K, Okuda H, Kurihara M, Okuno A, Niida S, Saito Y, *Takikawa O. NMR-based Metabolomics of Urine in a Mouse Model of Alzheimer's Disease: Identification of Oxidative Stress Biomarkers. J Clin Biochem Nutr. 52:133-138, 2013. |
| Matsuno K, Yamazaki H, Isaka Y, takai K, Unno Y, Ogo
N, Ishikawa Y,
Fujii S, *Takikawa O, Asai A. Novel candesartan derivatives
asindoleamine 2,3-dioxygenase inhibitors. Med. Chem. Comm，3:475-479,
2012. |
| Nakano S, Takai K, Isaka Y, Takahashi S, Unno Y, Ogo
N, Matsuno K, *Takikawa
O, Asai A. Identification of novel kynurenine
production-inhibitingbenzenesulfonamidederivatives in cancer cells.
Biochem Biophys Res Commun,419:556-561, 2012. |
| Wang D, Saga Y, Mizukami H, Sato N, Nonaka H,
Fujiwara H, Takei Y, Machida S, *Takikawa
O, Ozawa K, Suzuki M. Indoleamine-2,3-dioxygenase, an immunosuppressive
enzyme that inhibits naturalkiller cell function, as a useful target
for ovarian cancer therapy. Int J Oncol，40:929-934,2012. |
| Wright O#, *Yoshimi T#, Tunnacliffe
A (#: equally contributed). Recombinant production ofcathelicidin-derived antimicrobial peptides
in Escherichia coli using an inducible autocleaving enzyme tag. N
Biotechnol，29:352-358, 2012. |
| |
| [Patent pending] |
| PCT/JP2009/006760 |
| |
| |
